Vaxxinity, Inc. (VAXX)

NASDAQ: VAXX · IEX Real-Time Price · USD
1.98
-0.05 (-2.46%)
At close: Sep 30, 2022 4:00 PM
2.01
+0.03 (1.52%)
After-hours: Sep 30, 2022 7:42 PM EDT
-2.46%
Market Cap 249.53M
Revenue (ttm) 66,000
Net Income (ttm) -113.76M
Shares Out 126.02M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 81,063
Open 2.03
Previous Close 2.03
Day's Range 1.98 - 2.08
52-Week Range 1.51 - 22.77
Beta n/a
Analysts Buy
Price Target 15.30 (+672.7%)
Earnings Date Aug 8, 2022

About VAXX

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical tr... [Read more...]

Industry Biotechnology
IPO Date Nov 11, 2021
Employees 89
Stock Exchange NASDAQ
Ticker Symbol VAXX
Full Company Profile

Financial Performance

In 2021, Vaxxinity's revenue was $66,000, a decrease of -88.15% compared to the previous year's $557,000. Losses were -$137.18 million, 243.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for VAXX stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 672.73% from the latest price.

Price Target
$15.3
(672.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects...

2 weeks ago - GlobeNewsWire

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022

1 month ago - GlobeNewsWire

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

Summit is taking place July 26, 2022 from 11:00 AM ET – 3:15 PM ET

2 months ago - GlobeNewsWire

Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates

DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the ...

4 months ago - GlobeNewsWire

Why Did Vaxxinity (VAXX) Stock Gain 80% Today?

VAXX stock gained more than 80% on Friday after Vaxxinity announced it has enrolled patients for the next part of its trials. The post Why Did Vaxxinity (VAXX) Stock Gain 80% Today?

5 months ago - InvestorPlace

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants

OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a ne...

5 months ago - GlobeNewsWire

Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates

DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for th...

6 months ago - GlobeNewsWire

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced th...

6 months ago - GlobeNewsWire

Vaxxinity's COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Oth...

DALLAS, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced results from studies dem...

7 months ago - GlobeNewsWire

Vaxxinity (VAXX) Starts Dosing in Parkinson's Disease Study

Vaxxinity (VAXX) starts dosing patients in part B of a phase I study on its investigational Parkinson's disease vaccine candidate.

8 months ago - Zacks Investment Research

Vaxxinity Announces First Parkinson's Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

DALLAS, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first patient w...

8 months ago - GlobeNewsWire

Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

DALLAS, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the...

9 months ago - GlobeNewsWire

Vaxxinity Has a Rough Public Debut

Investors have trouble valuing the biotech's IPO.

10 months ago - The Motley Fool

Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters' Option to Purchase Additional Shares

DALLAS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its initia...

10 months ago - GlobeNewsWire

VAXX Stock Alert: 10 Things to Know About Newly Public Vaxxinity as Shares Soar

Shares of VAXX stock are trading higher today after last week's public debut. Could its Covid-19 vaccine candidate send shares even higher?

10 months ago - InvestorPlace

Vaxxinity enjoys warm Wall Street reception as stock trades 20% above IPO price

Vaxxinity Inc. VAXX, +19.23% started its public life with a big rally, as the Texas-based biotechnology company's stock was trading more 21.2% above its initial public offering price. The company said o...

10 months ago - Market Watch

Vaxxinity Announces Pricing of Initial Public Offering

DALLAS, Texas, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the pricing of its...

10 months ago - GlobeNewsWire